Tim Eisen

18.5k total citations · 4 hit papers
145 papers, 12.8k citations indexed

About

Tim Eisen is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Tim Eisen has authored 145 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Pulmonary and Respiratory Medicine, 85 papers in Molecular Biology and 57 papers in Cancer Research. Recurrent topics in Tim Eisen's work include Renal cell carcinoma treatment (78 papers), Renal and related cancers (48 papers) and Cancer Genomics and Diagnostics (45 papers). Tim Eisen is often cited by papers focused on Renal cell carcinoma treatment (78 papers), Renal and related cancers (48 papers) and Cancer Genomics and Diagnostics (45 papers). Tim Eisen collaborates with scholars based in United Kingdom, United States and France. Tim Eisen's co-authors include Martin Gore, Walter M. Stadler, Bernard Escudier, Brian Schwartz, Ronald M. Bukowski, Cezary Szczylik, Apurva A. Desai, Minghua Shan, Ronit Simantov and Sylvie Négrier and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Tim Eisen

143 papers receiving 12.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

2007 3.8k citations Bernard Escudier, Tim Eisen et al. New England Journal of Medicine profile →
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

2009 864 citations Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology profile →
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

2006 794 citations Mark J. Ratain, Tim Eisen et al. Journal of Clinical Oncology profile →
VHL, the story of a tumour suppressor gene

2014 560 citations Lucy Gossage, Tim Eisen et al. Nature reviews. Cancer profile →

Peers

Countries citing papers authored by Tim Eisen

Since Specialization

Citations

This map shows the geographic impact of Tim Eisen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Eisen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Eisen more than expected).

Fields of papers citing papers by Tim Eisen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Eisen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Eisen. The network helps show where Tim Eisen may publish in the future.

Co-authorship network of co-authors of Tim Eisen

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Eisen. A scholar is included among the top collaborators of Tim Eisen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Eisen. Tim Eisen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. 2022 ·Apollo (University of Cambridge) ·Bhavna Oza, Tim Eisen, Eleni Frangou, Grant D. Stewart, Axel Bex, A.W.S. Ritchie, Richard Kaplan, (unknown), Ian D. Davis, Martin R. Stockler, Laurence Albigès, Bernard Escudier, James Larkin, Steven Joniau, Barry W. Hancock, Gregers G. Hermann, Joaquim Bellmunt, Mahesh Parmar, Patrick Royston, Angela Meade	10
2	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma 2021 ·Clinical Cancer Research ·Andrew J. Armstrong, Andrew B. Nixon, (unknown), Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, Jorge A. García, Ulka N. Vaishampayan, Joel Picus, Robert E. Hawkins, John D. Hainsworth, Christian Kollmannsberger, Theodore F. Logan, Igor Puzanov, Lisa Pickering, Christopher W. Ryan, Andrew Protheroe, Daniel J. George, Susan Halabi	18
3	Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK 2020 ·BMC Cancer ·Robert D. Hawkins, Kate Fife, (unknown), Meng Wang, (unknown), (unknown), Tim Eisen, Athena Matakidou, Jason Gordon	11
4	What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial 2018 ·PubMed ·Nicola Jane Lawrence, Andrew Martin, Ian D. Davis, (unknown), Shomik Sengupta, Elizabeth Hovey, Xanthi Coskinas, Richard Kaplan, (unknown), A.W.S. Ritchie, Angela Meade, Tim Eisen, Prunella Blinman, Martin R. Stockler	4
5	Patients’ preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? 2017 ·Annals of Oncology ·Prunella Blinman, (unknown), Andrew Martin, (unknown), Shomik Sengupta, Elizabeth Hovey, Xanthi Coskinas, Richard Kaplan, A.W.S. Ritchie, Angela Meade, Tim Eisen, Martin R. Stockler	12
6	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial 2016 ·The Lancet Oncology ·Andrew J. Armstrong, Susan Halabi, Tim Eisen, Samuel Broderick, Walter M. Stadler, Robert J. Jones, Jorge A. García, Ulka N. Vaishampayan, Joel Picus, Robert E. Hawkins, John D. Hainsworth, Christian Kollmannsberger, Theodore F. Logan, Igor Puzanov, Lisa Pickering, Christopher W. Ryan, Andrew Protheroe, Christine M. Lusk, (unknown), Daniel J. George	311
7	VHL, the story of a tumour suppressor gene breakdown → 2014 ·Nature reviews. Cancer ·Lucy Gossage, Tim Eisen, Eamonn R. Maher	560
8	Regorafenib (BAY 73–4506): Stromal and Oncogenic Multikinase Inhibitor with Potential Activity in Renal Cell Carcinoma 2013 ·Current Oncology Reports ·(unknown), (unknown), Tim Eisen	9
9	Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology 2012 ·European Journal of Cancer ·Martin Gore, Joaquim Bellmunt, Tim Eisen, Bernard Escudier, G. Mickisch, J.-J. Patard, Camillo Porta, Alain Ravaud, Manuela Schmidinger, Patrick Schöffski, Cora N. Sternberg, Cezary Szczylik, Enrico De Nigris, Cosette M. Wheeler, (unknown)	13
10	Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group 2011 ·Clinical Cancer Research ·Judith Manola, Patrick Royston, Paul Elson, (unknown), Madhu Mazumdar, Sylvie Négrier, Bernard Escudier, Tim Eisen, Janice P. Dutcher, Michael B. Atkins, Daniel Yick Chin Heng, Toni K. Choueiri, Robert J. Motzer, Ronald M. Bukowski	148
11	Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial breakdown → 2009 ·Journal of Clinical Oncology ·Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Négrier, Christine Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, (unknown), Minghua Shan, Carol Peña, Chetan Lathia, Ronald M. Bukowski	864
12	Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer 2009 ·British Journal of Radiology ·S.A. Sohaib, Gary Cook, Steven Allen, Michael Hughes, Tim Eisen, Martin Gore	47
13	Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma 2009 ·Melanoma Research ·Tim Eisen, José Thomas, Wilson H. Miller, Martin Gore, Pascal Wolter, Petr Kavan, José A. López-Martín, Pilar Lardelli	28
14	Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma breakdown → 2007 ·New England Journal of Medicine ·Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Négrier, Christine Chevreau, E Solska, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sara M. Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M. Bukowski	3804
15	Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma breakdown → 2006 ·Journal of Clinical Oncology ·Mark J. Ratain, Tim Eisen, Walter M. Stadler, Keith T. Flaherty, Stan B. Kaye, Gary L. Rosner, Martin Gore, Apurva A. Desai, Amita Patnaik, Henry Q. Xiong, Eric K. Rowinsky, James L. Abbruzzese, Chenghua Xia, Ronit Simantov, Brian Schwartz, Peter J. O’Dwyer	794
16	Case‐control study of familial lung cancer risks in UK women 2005 ·International Journal of Cancer ·Athena Matakidou, Tim Eisen, Helen Bridle, Mary O’Brien, (unknown), Richard S. Houlston	24
17	Vinorelbine alternating oral and intravenous plus carboplatinin advanced non-small-cell lung cancer: results of a multicentre phase II study 2004 ·Annals of Oncology ·Mary O’Brien, Aleksandra Szczęsna, (unknown), Petr Zatloukal, Tim Eisen, Wolfgang Hartmann, Peter Kasan, (unknown), Florence Lefresne	17
18	Farnesyl transferase inhibitor SCH66336 is cytostatic, pro‐apoptotic and enhances chemosensitivity to cisplatin in melanoma cells 2003 ·International Journal of Cancer ·Keiran S.M. Smalley, Tim Eisen	79
19	Differentiation of human melanoma cells through p38 MAP kinase is associated with decreased retinoblastoma protein phosphorylation and cell cycle arrest 2002 ·Melanoma Research ·Keiran S.M. Smalley, Tim Eisen	30
20	Small-cell lung cancer 1995 ·The Lancet ·Tim Eisen, Tamas Hickish, Ian E. Smith, John Sloane, Suzanne A. Eccles	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact